VIVORYON THERAPEUTICS N.V.

Insiders Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Real-time Euronext Amsterdam Other stock markets 10:14:15 2024-05-17 am EDT			5-day change	1st Jan Change
0.788 ^EUR	+4.79%		-0.88%	-90.32%

Apr. 24	Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
Mar. 15	Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	Mar. 15	CI
Vivoryon Therapeutics N.V. Announces Board Appointments	23-09-15	CI
Vivoryon Therapeutics Promotes Chief Medical Officer to CEO	23-08-07	MT
Vivoryon Therapeutics N.V. Approves Board Appointments	23-06-21	CI
Vivoryon Therapeutics CEO to Step Down in FY24	23-06-16	MT
Vivoryon Therapeutics N.V. Announces Resignation of Ulrich Dauer as CEO	23-06-15	CI
Vivoryon Therapeutics N.V. Announces Resignation of Dinnies Johannes Von Der Osten, PhD, and Jörg Neermann, PhD from the Board of Directors	23-05-01	CI
Vivoryon Therapeutics N.V. Announces the Appointment of Dr. Claudia Riedl and Samir Shah to its Non-Executive Board of Directors	22-06-22	CI
Probiodrug AG has Changed its Name to Vivoryon Therapeutics AG	19-06-11	CI
Probiodrug AG Announces Management Changes	18-10-05	CI
Probiodrug AG Appoints Michael Schaeffer as Executive Vice President of Business and Strategy	18-09-04	CI
Probiodrug AG Announces Management Changes	18-04-23	CI
Probiodrug AG Announces Management Changes	16-08-12	CI
Probiodrug AG Appoints Mark Booth as Chief Business Officer	16-03-23	CI
Probiodrug AG Appoints Inge Lues as Member of the Management Board as Chief Development Officer	14-10-31	CI
Probiodrug AG Appoints Ronald Black as Chief Medical Officer and Inge Lues as Chief Development Officer	13-01-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW